telmisartan has been researched along with transforming growth factor beta in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 11 (73.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Fagard, RH; Lijnen, PJ; Petrov, VV | 1 |
| He, Y; Huang, Q; Jiang, J; Li, M; Liu, X; Ma, D; Wang, S; Xu, G; Yao, Y; Zhou, J; Zou, R | 1 |
| Albayrak, F; Bilen, H; Cetinkaya, R; Halici, Z; Keles, ON; Suleyman, H; Unal, B; Uyanik, A | 1 |
| Han, M; He, Y; Huang, Q; Jiang, JJ; Liu, XC; Xu, G; Yao, Y; Zou, R | 1 |
| Gaikwad, AB; Mulay, SR; Tikoo, K | 1 |
| Deng, Z; Lin, F; Lin, H; Sun, C; Yu, H; Zhou, C; Zhu, P; Zhuo, X | 1 |
| Azuma, J; Iekushi, K; Iwabayashi, M; Kusunoki, H; Morishita, R; Okayama, K; Otsu, R; Rakugi, H; Sanada, F; Taniyama, Y | 1 |
| Fujimoto, M; He, P; Honjo, S; Ishibashi, R; Ishikawa, T; Koshizaka, M; Mezawa, M; Okabe, E; Onishi, S; Saito, Y; Sato, S; Takemoto, M; Tokuyama, H; Tsurutani, Y; Ueda, S; Yokote, K | 1 |
| Abbas, H; Ali, R; Geirsson, A; Hashim, S; Li, W; Sanchez, JA; Singh, M; Tellides, G | 1 |
| Ganburged, G; Moriyama, K; Suda, N | 1 |
| Chai, Y; Ho, TV; Iwata, J; Pelikan, RC; Sanchez-Lara, PA; Suzuki, A | 1 |
| Abe, T; Aukema, HM; Horie, S; Kugita, M; Nagao, S; Nakanishi, K; Sasaki, M; Yamaguchi, T; Yoshihara, D | 1 |
| Chen, CS; Feng, J; Jiang, F; Qin, X; Tao, T; Wang, T; Zhang, R | 1 |
| Bi, G; Cao, K; Fang, D; He, Y; Li, Z; Song, X; Wang, F; Wei, Y; Wu, J; Yang, J; Zhang, Z | 1 |
| Fang, T; Shen, Q; Wu, G; Xu, Y; Yang, J; Yang, Y; Zhang, J; Zuo, T | 1 |
15 other study(ies) available for telmisartan and transforming growth factor beta
| Article | Year |
|---|---|
Induction of cardiac fibrosis by angiotensin II.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Benzoates; Cells, Cultured; Collagen; Culture Media, Serum-Free; Dose-Response Relationship, Drug; Fibroblasts; Fibrosis; Lisinopril; Male; Myocardium; Rats; Rats, Wistar; Telmisartan; Time Factors; Transforming Growth Factor beta | 2000 |
Telmisartan but not valsartan inhibits TGF-beta-mediated accumulation of extracellular matrix via activation of PPARgamma.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Cells, Cultured; Extracellular Matrix; Glomerulosclerosis, Focal Segmental; Mesangial Cells; PPAR gamma; Rats; Telmisartan; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan | 2008 |
Does telmisartan prevent hepatic fibrosis in rats with alloxan-induced diabetes?
Topics: Alloxan; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Diabetes Mellitus, Experimental; Fibrosis; Immunohistochemistry; Liver; Male; Microscopy, Electron; Rats; Rats, Wistar; Telmisartan; Transforming Growth Factor beta | 2009 |
PPARgamma agonists inhibit TGF-beta-PKA signaling in glomerulosclerosis.
Topics: Actins; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Cells, Cultured; Chromans; Collagen Type IV; Cyclic AMP Response Element-Binding Protein; Cyclic AMP-Dependent Protein Kinases; Gene Expression Regulation; Glomerular Mesangium; Glomerulonephritis; Hypoglycemic Agents; PPAR gamma; Rats; Signal Transduction; Telmisartan; Thiazolidinediones; Transfection; Transforming Growth Factor beta; Troglitazone | 2010 |
Combination of aspirin with telmisartan suppresses the augmented TGFbeta/smad signaling during the development of streptozotocin-induced type I diabetic nephropathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Benzimidazoles; Benzoates; Cyclooxygenase 2; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Gene Expression Regulation; Inflammation; Male; NF-kappa B; Oxidative Stress; Rats; Rats, Sprague-Dawley; Signal Transduction; Smad Proteins; Streptozocin; Telmisartan; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2010 |
Synergistic effects of telmisartan and pyridoxamine on early renal damage in spontaneously hypertensive rats.
Topics: Animals; Benzimidazoles; Benzoates; Drug Synergism; Glycation End Products, Advanced; Kidney; Male; Malondialdehyde; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Protective Agents; Pyridoxamine; Rats; Rats, Inbred SHR; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Superoxide Dismutase; Telmisartan; Transcription Factor RelA; Transforming Growth Factor beta | 2012 |
Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Antibodies; Benzimidazoles; Benzoates; Cells, Cultured; Disease Models, Animal; Fibroblasts; Hepatocyte Growth Factor; Hydronephrosis; Kidney; Losartan; Male; Mice; Mice, Knockout; PPAR gamma; Receptor, Angiotensin, Type 1; Signal Transduction; Telmisartan; Transforming Growth Factor beta; Ureteral Obstruction | 2012 |
An angiotensin II type 1 receptor blocker prevents renal injury via inhibition of the Notch pathway in Ins2 Akita diabetic mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Calcium-Binding Proteins; Cells, Cultured; Diabetes Mellitus; Diabetic Nephropathies; Intercellular Signaling Peptides and Proteins; Jagged-1 Protein; Kidney Glomerulus; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Receptor, Notch1; Serrate-Jagged Proteins; Signal Transduction; Telmisartan; Transforming Growth Factor beta; Vascular Endothelial Growth Factor A | 2012 |
Modulation of transforming growth factor-β signaling and extracellular matrix production in myxomatous mitral valves by angiotensin II receptor blockers.
Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Biphenyl Compounds; Cells, Cultured; Collagen; Elastic Tissue; Extracellular Matrix Proteins; Fibrosis; Gene Expression Regulation; Genetic Diseases, X-Linked; Heart Defects, Congenital; Humans; Losartan; Mitral Valve Insufficiency; Mitral Valve Prolapse; Myxoma; Polymerase Chain Reaction; Signal Transduction; Smad2 Protein; Smad3 Protein; Telmisartan; Tetrazoles; Transforming Growth Factor beta; Vimentin | 2012 |
Effect of angiotensin II receptor blocker on experimental periodontitis in a mouse model of Marfan syndrome.
Topics: Alveolar Bone Loss; Angiotensin Receptor Antagonists; Animals; Bacteroidaceae Infections; Benzimidazoles; Benzoates; Bone Resorption; Disease Models, Animal; Inflammation; Interleukin-17; Male; Marfan Syndrome; Mice; Osteoclasts; Periodontitis; Porphyromonas gingivalis; Telmisartan; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2013 |
Modulation of lipid metabolic defects rescues cleft palate in Tgfbr2 mutant mice.
Topics: Animals; Benzimidazoles; Benzoates; Cell Line; Cell Proliferation; Cleft Palate; Embryo, Mammalian; Female; Gene Expression Regulation, Developmental; Hedgehog Proteins; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation; p38 Mitogen-Activated Protein Kinases; Protein Serine-Threonine Kinases; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Signal Transduction; Telmisartan; Transforming Growth Factor beta | 2014 |
Telmisartan ameliorates fibrocystic liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease.
Topics: Angiotensin II; Animals; Benzimidazoles; Benzoates; Blood Pressure; Cell Proliferation; Cysts; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Female; Hepatocytes; Humans; Kidney Function Tests; Liver; Liver Diseases; Liver Function Tests; Male; Organ Size; Polycystic Kidney, Autosomal Recessive; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Signal Transduction; Telmisartan; Transforming Growth Factor beta | 2013 |
Serum Levels of IL-1 β , IL-6, TGF- β , and MMP-9 in Patients Undergoing Carotid Artery Stenting and Regulation of MMP-9 in a New In Vitro Model of THP-1 Cells Activated by Stenting.
Topics: Aged; Benzimidazoles; Benzoates; Carotid Stenosis; Cells, Cultured; Chemokine CCL2; ets-Domain Protein Elk-1; Extracellular Signal-Regulated MAP Kinases; Female; Human Umbilical Vein Endothelial Cells; Humans; Interleukin-1beta; Interleukin-6; Male; Matrix Metalloproteinase 9; Middle Aged; PPAR gamma; Stents; Telmisartan; Transforming Growth Factor beta; Vascular Cell Adhesion Molecule-1 | 2015 |
Adjunctive therapy with statins reduces residual albuminuria/proteinuria and provides further renoprotection by downregulating the angiotensin II-AT1 pathway in hypertensive nephropathy.
Topics: Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Benzoates; Down-Regulation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Renal; Kidney; Male; Nephritis; NF-kappa B; Proteinuria; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Signal Transduction; Telmisartan; Transforming Growth Factor beta | 2017 |
Chemo-Photothermal Combination Cancer Therapy with ROS Scavenging, Extracellular Matrix Depletion, and Tumor Immune Activation by Telmisartan and Diselenide-Paclitaxel Prodrug Loaded Nanoparticles.
Topics: Animals; Drug Delivery Systems; Glutathione; Humans; Metal Nanoparticles; Paclitaxel; Photothermal Therapy; Platinum; Prodrugs; Reactive Oxygen Species; Telmisartan; Transforming Growth Factor beta; Tumor Microenvironment | 2020 |